Background: Stent strut malapposition correlates with poor intimal coverage and this may increase the risk of late stent thrombosis. At present, there is limited data on whether stent strut thickness and stent design impact on acute apposition. We aimed to investigate the influence of stent strut thickness and design on acute stent strut apposition (SSA) immediately following drug-eluting stent (DES) implantation using optical coherence tomography (OCT), a technique with higher resolution and fewer artefacts than intravascular ultrasound.

Methods: Thirty-six DES in 23 patients (25 lesions) were studied by OCT. SSA was defined as embedded when a strut was buried in the intima for more than half its thickness, protruding when apposed to the intima but not embedded and malapposed when there was no intimal contact.

Results: Cypher Select stents were implanted in 52%, Taxus Liberte in 32%, Costar in 12% and Endeavour in 4%. A total of 6402 struts were evaluated. Despite stent optimisation using balloons with a final balloon/artery ratio of 1.26+/-0.19 at a maximum inflation pressure of 17.5+/-3.0 atm, only 57.1+/-20.7% of struts were embedded, whereas 33.8+/-18.4% were protruding and 9.1+/-7.4% were malapposed. Stent type was a strong predictor of malapposition on logistic multilevel analysis (OR 3.95, 95%CI: 1.27-12.23, p=0.017). At 12 months follow-up, there were no adverse clinical events.

Conclusion: Despite angiographic optimisation with high pressures and adequately sized balloons, malapposed stent struts are frequently found in complex coronary lesions and more often following the implantation of Cypher Select stents which have a thicker stent strut and closed cell design. With no adverse clinical events at 12 months follow-up, this likely represents a benign phenomenon at least as long as combined anti-platelet therapy is maintained.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2008.05.069DOI Listing

Publication Analysis

Top Keywords

stent strut
20
strut thickness
12
stent
11
cell design
8
optical coherence
8
coherence tomography
8
cypher select
8
select stents
8
malapposed stent
8
months follow-up
8

Similar Publications

Background: Elective unprotected left main (ULM) percutaneous coronary intervention (PCI) has long-term mortality rates comparable to surgical revascularization, thanks to advances in drug-eluting stent (DES) design, improved PCI techniques, and frequent use of intravascular imaging. However, urgent PCI of ULM culprit lesions remains associated with high in-hospital mortality and unfavourable long-term outcomes, including DES restenosis and stent thrombosis (ST). This analysis aimed to examine the long-term outcomes and healing of DES implanted in ULM during primary PCI using high-resolution optical coherence tomography (OCT) imaging.

View Article and Find Full Text PDF

Polymeric coronary stents, like the ABSORB™, are commonly used to treat atherosclerosis due to their bioresorbable and cell-compatible polymer structure. However, they face challenges such as high strut thickness, high elastic recoil, and lack of radiopacity. This study aims to address these limitations by modifying degradable stents produced by additive manufacturing with poly(lactic acid) (PLA) and poly(ε-caprolactone) (PCL) with degradable metallic coatings, specifically zinc (Zn) and magnesium (Mg), deposited via radiofrequency (rf) magnetron sputtering.

View Article and Find Full Text PDF

Background: Left main coronary bifurcation lesions account for 50% of left main coronary artery disease cases. Although a drug-coated balloon (DCB) has the advantages of immediate release of the drug to the arterial wall and no remaining struts, there is no conclusive evidence to support DCB use.

Methods & Results: We conducted a systematic review in compliance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement.

View Article and Find Full Text PDF

Background: To compare the performance of a new-generation cobalt-chromium balloon-expandable bare metal stent with a stainless steel platform for the treatment of iliac occlusive disease.

Methods: Consecutive patients treated for symptomatic iliac occlusive disease between 2014 and 2021 with the cobalt-chromium Dynetic-35 or the stainless steel Dynamic platform were retrospectively evaluated. Outcome measures included technical success, device- or procedure-related death, clinically-driven target lesion revascularization (CD-TLR), primary patency, and major index limb amputation up to 12 months.

View Article and Find Full Text PDF

Current situation and overview of resorbable magnesium scaffolds: a perspective for overcoming the remaining issues of polymeric bioresorbable scaffold.

Cardiovasc Interv Ther

December 2024

Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.

Bioresorbable scaffolds (BRS) were developed as an innovative solution to overcome the limitations of metallic stents. While polymeric BRS initially demonstrated comparable clinical outcomes to drug-eluting stent (DES) in clinical trials, subsequent large-scale studies revealed that patients implanted with polymeric BRS experienced higher rates of scaffold thrombosis (ScT) and target lesion failure compared to those with metallic stents. Resorbable magnesium scaffolds (RMS) have emerged as a promising alternative owing to magnesium's natural degradability and favorable mechanical properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!